Bevacizumab in the treatment of HER2-negative breast cancer

Código QR

Bevacizumab in the treatment of HER2-negative breast cancer

Vito LorussoOncologic Institute, Vito Fazzi Hospital, Lecce, ItalyAbstract: Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Be...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Vito Lorusso
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/63902e14daea4d16883e5a78a2bcb251
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Current neoadjuvant treatment options for HER2 positive breast cancer
por: Abdel-Razeq H, et al.
Publicado: (2011)

Bevacizumab in the treatment of ovarian cancer
por: Ramez N Eskander, et al.
Publicado: (2011)

HER2 breast cancer therapies: a review
por: Conleth G Murphy, et al.
Publicado: (2009)

Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
por: Jia Li, et al.
Publicado: (2009)

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
por: Shogo Nakamoto, et al.
Publicado: (2021)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Bella Kaufman, et al.
Publicado: (2008)

Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
por: Toshiaki Utsumi, et al.
Publicado: (2021)

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
por: Abdel Kader Y, et al.
Publicado: (2013)

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
por: Merel Gijsen, et al.
Publicado: (2010)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mary F Mulcahy
Publicado: (2008)

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
por: Swanner J, et al.
Publicado: (2015)

Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells
por: Li J, et al.
Publicado: (2017)

Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer
por: Sun JZ, et al.
Publicado: (2014)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Avisek Majumder, et al.
Publicado: (2021)

Treatment of oral squamous cell carcinoma using anti-HER2 immunonanoshells
por: Fekrazad R, et al.
Publicado: (2011)

Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer
por: Naruphontjirakul P, et al.
Publicado: (2019)

Near-infrared quantum dots for HER2 localization and imaging of cancer cells
por: Rizvi SB, et al.
Publicado: (2014)

Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer
por: Chen H, et al.
Publicado: (2013)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
por: Nindo B. Punturi, et al.
Publicado: (2021)

99mTc-Radiolabeled Silica Nanocarriers for Targeted Detection and Treatment of HER2-Positive Breast Cancer
por: Rainone P, et al.
Publicado: (2021)

Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment
por: Zheng D, et al.
Publicado: (2020)

Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells
por: Shen Y, et al.
Publicado: (2018)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Laura Pizzuti, et al.
Publicado: (2021)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain S, et al.
Publicado: (2012)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ho Hyun Ryu, et al.
Publicado: (2021)

Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle
por: Zhang C, et al.
Publicado: (2020)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani P, et al.
Publicado: (2015)

Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer
por: Thomas Kunzke, et al.
Publicado: (2021)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
por: Board Editorial
Publicado: (2021)

Development of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer
por: Rainone P, et al.
Publicado: (2017)

Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
por: Gomari H, et al.
Publicado: (2019)

Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study
por: Lin X, et al.
Publicado: (2021)

Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer
por: Jin X, et al.
Publicado: (2020)

Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer
por: Kanako Hagio, et al.
Publicado: (2021)

Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
por: Chaturbhuj Agrawal, et al.
Publicado: (2021)

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
por: Bernard Escudier, et al.
Publicado: (2008)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
por: Yuefeng Wang, et al.
Publicado: (2017)

Role of pertuzumab in the treatment of HER2-positive breast cancer
por: Hubalek M, et al.
Publicado: (2012)

New developments in the treatment of HER2-positive breast cancer
por: Nahta R
Publicado: (2012)

A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer
por: Yalikong A, et al.
Publicado: (2021)